Pharmcokinetic and pharmacodynamic considerations for the anticholinergic burden scale of drugs

Abstract

Older adults frequently have many systemic diseases that require treatment with multiple drugs, and thus anticholinergic adverse effect by polypharmacy is a significant concern in the management of older adults. The accuracy of the anticholinergic burden rating may be increased by considering pharmacokinetic and pharmacodynamic factors such as biophase drug concentrations, the pharmacologically active metabolites formed after drug administration, and muscarinic receptor‐mediated effects. Therefore, a pharmacological evidence‐based burden scale that considers pharmacokinetic and pharmacodynamic factors is expected to be a more optimal tool for precisely assessing the anticholinergic burden, specifically risk reductions in anticholinergic adverse events in the poly‐medicated elderly. Geriatr Gerontol Int 2023; ••: ••–••.